Analyst Price Targets — BBNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 28, 2026 11:54 am | Patrick Wood | UBS | $22.00 | $15.99 | TheFly | Beta Bionics resumed with a Buy at UBS |
| July 15, 2026 10:20 am | — | Goldman Sachs | $19.00 | $16.86 | TheFly | Beta Bionics price target raised to $19 from $17 at Goldman Sachs |
| July 13, 2026 1:48 pm | — | Truist Financial | $22.00 | $17.26 | TheFly | Beta Bionics price target raised to $22 from $18 at Truist |
| May 27, 2026 10:17 am | — | Goldman Sachs | $17.00 | $11.72 | TheFly | Beta Bionics price target lowered to $17 from $19 at Goldman Sachs |
| February 18, 2026 1:42 pm | — | Lake Street | $20.00 | $12.45 | TheFly | Beta Bionics price target lowered to $20 from $40 at Lake Street |
| February 18, 2026 12:47 pm | — | Robert W. Baird | $14.00 | $13.97 | TheFly | Beta Bionics price target lowered to $14 from $28 at Baird |
| February 18, 2026 11:47 am | Jonathan Block | Stifel Nicolaus | $22.00 | $13.97 | TheFly | Beta Bionics price target lowered to $22 from $25 at Stifel |
| February 8, 2026 9:13 pm | — | UBS | $24.00 | $13.08 | TheFly | Beta Bionics initiated with a Buy at UBS |
| February 4, 2026 1:09 pm | — | Stifel Nicolaus | $25.00 | $14.06 | TheFly | Beta Bionics price target lowered to $25 from $31 at Stifel |
| February 2, 2026 2:54 pm | — | Truist Financial | $25.00 | $13.90 | TheFly | Beta Bionics price target lowered to $25 from $37 at Truist |
Latest News for BBNX
BlackRock Inc. bought a new position in Beta Bionics, Inc. (NASDAQ: BBNX) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 3,340,171 shares of the company's stock, valued at approximately $52,340,000. BlackRock Inc. owned 7.42% of Beta Bionics as of its most
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business…
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
SAN DIEGO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business…
Beta Bionics, Inc. (NASDAQ: BBNX - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BBNX.
U.S. House Trading
No House trades found for BBNX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.